Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3357354 | 0.86 | KMT2A (0.47) | CDK2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL7508094 | 0.84 | CDK2 (0.46) | CDK2MAPTL3MBTL1NPC1MEN1 | |
| SCHEMBL6488744 | 0.82 | MAPT (0.49) | CDK2MAPTNPC1MCL1POLB | |
| SCHEMBL5327849 | 0.82 | CDK2 (0.56) | CDK2MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL3358211 | 0.79 | MAPT (0.47) | CDK2MAPTNPC1MEN1KMT2A | |
| SCHEMBL29263665 | 0.79 | NR4A2 (0.59) | CDK2MAPTNPC1MEN1KMT2A | |
| SCHEMBL27709706 | 0.79 | CDK2 (0.46) | CDK2MAPTNPC1MEN1KMT2A | |
| SCHEMBL3351542 | 0.78 | ALDH1A1 (0.46) | CDK2MAPTNPC1MEN1KMT2A | |
| SCHEMBL3353911 | 0.78 | ALDH1A1 (0.45) | CDK2MAPTL3MBTL1NPC1MEN1 | |
| SCHEMBL28265756 | 0.78 | MAPT (0.46) | CDK2MAPTNPC1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2141163-A1 | Substituted thiazolidinones, their production and utilisation as medicine | Bayer Schering Pharma AG (DE) | 2010-01-06 | — | — | EP | disclosed |
| EP-2141163-A1 | Substituted thiazolidinones, their production and utilisation as medicine | Bayer Schering Pharma AG (DE) | 2010-01-06 | — | — | EP | disclosed |